
-
2002
Company Description
Alnylam Pharmaceuticals develops novel therapeutics-based RNAi and provides overviews of recent drug development programs.
Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
-
Manufacturer:
Science and Engineering -
Formed:
2002 -
Company Website:
-
Company E-mail:
-
Company Address:
300 Third Street, 3rd FloorCambridge, MAUnited States -
CEO:
- David Konys
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits